AB-002 (Akso Biopharmaceutical)

N/A

Report date: 2022/02/14 17:06:54

Base Information

Drug NameAB-002 (Akso Biopharmaceutical)
Drug Alias NameAB-002
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionProgrammed death-ligand 1 blockersProgrammed death-ligand 2 inhibitorsInterleukin-15 receptor subunit alpha agonists
TargetsProgrammed death-ligand 1Programmed death-ligand 2Interleukin-15 receptor subunit alpha
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAkso Biopharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesAkso Biopharmaceutical IncHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A